Ironwood Pharmaceuticals, Inc. beat EPS estimates 56% of the time across 16 reported quarters (9 beats, 7 misses), averaging -5.5% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $0.26 | $0.31 | +19.2% | Beat | Q2 FY26 call |
| Q1 FY26 | not reported | $0.24 | not reported | not reported | |
| Q4 FY25 | not reported | $-0.01 | not reported | not reported | |
| Q3 FY25 | not reported | $0.24 | not reported | not reported | |
| Q2 FY25 | not reported | $0.14 | not reported | not reported | |
| Q1 FY25 | not reported | $-0.14 | not reported | not reported | |
| Q4 FY24 | not reported | $0.02 | not reported | not reported | |
| Q3 FY24 | not reported | $0.02 | not reported | not reported | |
| Q2 FY24 | $0.17 | $0.00 | -100.0% | Miss | |
| Q1 FY24 | not reported | $-0.02 | not reported | not reported | |
| Q4 FY23 | $0.20 | $0.00 | -100.0% | Miss | |
| Q3 FY23 | $0.17 | $0.12 | -29.4% | Miss |
Back to IRWD overview · IRWD holders · IRWD KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.